← Leaderboards
Florian Krammer
Icahn School Of Medicine At Mount Sinai
$130,401,178
Attributed
$130,802,408
Total exposure
12
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $31M · FY2015–25$50M$37.5M$25M$12.5M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$130,802,408 · 12
By mechanism
N01$121,248,766 · 2
R01$3,432,792 · 2
P01$1,865,881 · 1
U54$1,742,915 · 2
U19$819,718 · 2
R25$802,461 · 1
Top collaborators
- Christine Marizzi3 shared
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Viviana A Simon$21,556,427
- Benjamin Goldman-Israelow$1,110,912
- Michael Schotsaert$3,271,645
- Goran Bajic$3,116,277
- Stephen Mark Tompkins$2,901,976
Others in their field
Top investigators on “Immunity”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$470,748,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Judith S. Currier · University Of California Los Angeles$334,425,492
Research focus
ImmunityDesignVaccinesVaccine DesignImmune ResponseVirusVaccine CandidateInfectionAntibodiesVaccinationInfluenza Virus VaccineAntibody ResponseClinical TrialsEfficacy TestingResponseIn VivoInnovationAntigensFuture2019-NcovImmunogenicityInfluenzavirusMediatingEpitopes
Grant awards (40)
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH$12,837,354
N01 · FY2025 · AI · contact PI
Development of a pan-betacoronavirus vaccine$626,637
P01 · FY2025 · AI · contact PI
New York City Virus Hunters - A Community Science Initiative$265,309
R25 · FY2025 · GM · contact PI
Immune phenotyping of human immune responses to SARS CoV-2 vaccination and infection$144,279
U19 · FY2025 · AI · contact PI
Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component A: Vaccine Center$15,829,335
N01 · FY2024 · AI · contact PI
Development of a pan-betacoronavirus vaccine$626,637
P01 · FY2024 · AI · contact PI
New York City Virus Hunters - A Community Science Initiative$265,309
R25 · FY2024 · GM · contact PI
Immune phenotyping of human immune responses to SARS CoV-2 vaccination and infection$191,272
U19 · FY2024 · AI · contact PI
Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component A: Vaccine Center, SARS-CoV-2$169,106
N01 · FY2024 · AI · contact PI
Project 1: Characterization of the Antibody Response to SARS-CoV-2 in Lung Cancer Patients$119,920
U54 · FY2024 · CA · contact PI
DEVELOPMENT OF A VACCINE CANDIDATE FOR CORONAVIRUSES$15,898,493
N01 · FY2023 · AI · contact PI
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA RESEARCH$13,997,120
N01 · FY2023 · AI · contact PI
Development of a pan-betacoronavirus vaccine$612,607
P01 · FY2023 · AI · contact PI
New York City Virus Hunters - A Community Science Initiative$271,843
R25 · FY2023 · GM · contact PI
Immune phenotyping of human immune responses to SARS CoV-2 vaccination and infection$200,951
U19 · FY2023 · AI · contact PI
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA RESEARCH$11,756,332
N01 · FY2022 · AI · contact PI
Immune phenotyping of human immune responses to SARS CoV-2 vaccination and infection$283,216
U19 · FY2022 · AI · contact PI
Project 1: Characterization of the Antibody Response to SARS-CoV-2 in Lung Cancer Patients$226,649
U54 · FY2022 · CA · contact PI
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA RESEARCH$13,681,100
N01 · FY2021 · AI · contact PI
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM$2,900,000
N01 · FY2021 · AI · contact PI
CIVICS PROGRAM - SARS-CoV-2 STUDIES$1,198,308
N01 · FY2021 · AI · contact PI
CIVICS PROGRAM - SARS-CoV-2 STUDIES$457,311
N01 · FY2021 · AI · contact PI
Determining the induction of hemagglutinin stalk and neuraminidase antibody responses after LAIV vaccination in children$211,875
R21 · FY2021 · AI · contact PI
Antibody responses in humans after infection with avian influenza viruses$200,000
R01 · FY2021 · AI · contact PI
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM$11,979,672
N01 · FY2020 · AI · contact PI
CIVICS)PROGRAM - SARS-CoV-2 STUDIES$7,342,586
N01 · FY2020 · AI · contact PI
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER$3,202,049
N01 · FY2020 · AI · contact PI
Project 1: Characterization of the Antibody Response to SARS-CoV-2 in Lung Cancer Patients$1,396,346
U54 · FY2020 · CA · contact PI
Broad humoral protection induced by influenza B neuraminidase-based immunogens$423,750
R01 · FY2020 · AI · contact PI
Determining the induction of hemagglutinin stalk and neuraminidase antibody responses after LAIV vaccination in children$254,250
R21 · FY2020 · AI · contact PI
Antibody responses in humans after infection with avian influenza viruses$200,000
R01 · FY2020 · AI · contact PI
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER$10,000,000
N01 · FY2019 · AI · contact PI
Broad humoral protection induced by influenza B neuraminidase-based immunogens$423,750
R01 · FY2019 · AI · contact PI
Antibody responses in humans after infection with avian influenza viruses$200,000
R01 · FY2019 · AI · contact PI
Broad humoral protection induced by influenza B neuraminidase-based immunogens$808,418
R01 · FY2018 · AI · contact PI
Antibody responses in humans after infection with avian influenza viruses$200,000
R01 · FY2018 · AI · contact PI
Broad humoral protection induced by influenza B neuraminidase-based immunogens$423,750
R01 · FY2017 · AI · contact PI
Antibody responses in humans after infection with avian influenza viruses$200,000
R01 · FY2017 · AI · contact PI
Broad humoral protection induced by influenza B neuraminidase-based immunogens$353,124
R01 · FY2016 · AI · contact PI
Broad humoral protection induced by influenza B neuraminidase-based immunogens$423,750
R56 · FY2015 · AI · contact PI